The company has another potential $40mm in upcoming approval milestones associated with rida. When you take their current cash position and burn rate into account and factor in that MRK is covering the co-promote expenses, there is no immediate pressure to raise $'s - even without partnering EU or Asia. My guess is the company will look to time the next financing around the rida approval and/or run-up to the ponatinib filing (that being said, harvey has surprised me with financings before,lol)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.